NCT03327155View on ClinicalTrials.gov

Western Australian Pre-exposure Prophylaxis for HIV Implementation Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

900

Participants

Timeline

Start Date

November 16, 2017

Primary Completion Date

April 30, 2019

Study Completion Date

July 20, 2020

Conditions
HIV Prevention
Interventions
DRUG

Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)

One tablet, containing 300mg of TDF and 200mg of FTC once daily with food.

Trial Locations (4)

6000

Royal Perth Hospital Sexual Health Clinic, Perth

6005

M Clinic, Perth

6050

GP on Beaufort, Mount Lawley

6160

South Terrace Sexual Health Clinic, Fremantle

Sponsors

Lead Sponsor

Kirby Institute
All Listed Sponsors
collaborator

Government of Western Australia, Department of Health

UNKNOWN

collaborator

Western Australia AIDS Council

UNKNOWN

lead

Kirby Institute

OTHER_GOV

NCT03327155 - Western Australian Pre-exposure Prophylaxis for HIV Implementation Trial | Biotech Hunter | Biotech Hunter